Focal Intraoperative Radiotherapy of Brain Metastases

Brain Metastases, Adult Clinical Trial

Official title:

Focal Intraoperative Radiotherapy After Resection of Brain Metastases

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03789149
• Other study ID #: 2315/17
• Status: Terminated
• Phase: Phase 2
• Start date: May 2, 2019
• Est. completion date: June 30, 2022

Study information

• Verified date: July 2022
• Source: AC Camargo Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Brain metastases (BM) are the most prevalent tumors of the central nervous system (CNS), with a ratio of 10: 1 in relation to primary tumors. In prospective studies, whole-brain radiotherapy (WBRT) reduced the risk of local recurrence after resection of brain metastases from 46-59% to 10-28%. Furthermore, WBRT reduces the incidence of new metastases and death from disease, but no apparent improvement in overall survival (OS). Due to the potential neurocognitive effects associated with WBRT compared to isolated focal approach, several authors have suggested delaying WBRT and perform focal adjuvant RT after resection of isolated BM. In this context, intraoperative radiotherapy (IORT) in the cavity after resection of BM may be an appealing option. The primary objectives of this study are to evaluate local control (LC) and the control of brain disease (LC associated with the absence of new distant BM) after IORT for one completely resected supratentorial BM in the presence of up to 10 lesions suggestive of BM.

Description:

Brain metastases (BM) are the most prevalent tumors of the central nervous system (CNS), with a ratio of 10: 1 in relation to primary tumors. This type of metastasis occurs in 20-40% of cancer patients and are related to significant morbidity and mortality. In prospective studies, whole-brain radiotherapy (WBRT) reduced the risk of local recurrence after resection of brain metastases from 46-59% to 10-28%. Furthermore, WBRT reduces the incidence of new metastases and death from disease, but no apparent improvement in overall survival (OS). Due to the potential neurocognitive effects associated with WBRT compared to isolated focal approach, several authors have suggested delaying WBRT and perform focal adjuvant RT after resection of isolated BM. The utilization of intraoperative radiotherapy (IORT) in the cavity after resection of primary or BM has been described in the literature, the majority of reports describes performing brachytherapy with iodine seeds or interstitial radiosurgery. However, there is a paucity of information regarding the use of IORT with low energy X-ray for focal treatment after resection of brain BM. The objectives of this study are evaluate local control (LC), the control of brain disease in patients with metastatic brain disease (up to 10 lesions) submitted to focal IORT to an isolated surgical cavity, evaluate overall survival (OS), evaluate the frequency of radiation necrosis and correlate the prognostic factors related to the patient with OS and the parameters of the treatment (dose, volume, lesion location) with the LC and radiation necrosis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: June 30, 2022
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >18 years
• Histologically confirmed diagnosis of invasive cancer in the presence of up to 10 lesions suggestive of BM
• Indication of resection of single lesion suggestive of BM and evidence of macroscopic complete resection
• Patient consent to participate in the study

Exclusion Criteria:

• Previous cranial radiotherapy
• Any kind of antineoplasic systemic treatment for less than 7 days of the procedure
• Cavities with proximity < 10 mm from the brainstem or optical pathway.
• Pregnant patients

Related Conditions & MeSH terms

• Brain Metastases, Adult
• Brain Neoplasms
• Central Nervous System Metastases
• Neoplasm Metastasis
• Neoplasms, Second Primary

Intervention

Radiation:
• Intraoperative Radiotherapy
Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG) consisting of a small source of low energy x-rays (30-50 kV) mounted on a mechanical arm with six degrees of freedom. The resulting dose distribution is isotropic around the tip of the X-ray source. A set of spherical applicators with diameters ranging from 1.5 to 5 cm is available to connect to the source. The treatment time may vary from 20-30 minutes with the suggested dose of 18 Gy to the resection cavity to a depth of 1 mm.

Locations

Country	Name	City	State
Brazil	AC Camargo Cancer Center	São Paulo	SP

Sponsors (2)

Lead Sponsor	Collaborator
AC Camargo Cancer Center	Carl Zeiss Meditec AG

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Local control (LC)	Rate of local failure in the surgical cavity	1 year
Primary	Control of Brain Disease (CBD)	Rate of control in the brain outside	1 year
Secondary	Overall Survival (OS)	Rate of death related to any cause	1 year
Secondary	Frequency of radiation necrosis	Imaging evaluation	1 year